Efficacy the WINLEVI® Way

Models shown are not actual patients.
Winlevi provides you with another option in your treatment approach
Treatment Success: IGA
Treatment success at week 121,2
Twice-daily WINLEVI (clascoterone) cream 1% monotherapy resulted in the following:
Significantly increased investigator's global assessment (IGA) treatment success2*
Treatment success criteria
*Stringent IGA success was defined as at least a 2-point reduction in IGA score from baseline and an IGA score of 0 (clear) or 1 (almost clear).1
STUDY DESIGN: In 2 identical, randomized, double-blind, vehicle controlled trials with a total of 1421 enrolled subjects 12 years of age and older with facial acne vulgaris, WINLEVI was statistically superior over vehicle for all 3 coprimary endpoints,3 including IGA success* and absolute change from baseline in inflammatory and noninflammatory lesion counts.1 Mean percent change from baseline in total, inflammatory, and noninflammatory lesion counts, and absolute change from baseline in total lesion counts were secondary endpoints. Data shown are pooled efficacy results for patients ages 12 and older.
Focus on before-and-after results
See the difference for patients on twice-daily WINLEVI (clascoterone) cream 1% monotherapy at week 121
Most common adverse reactions occurring in 7% to 12% of patients are erythema/

Actual female patient from Winlevi clinical trial
Treatment Success: Lesion Count
Treatment success at week 121,2
Twice-daily WINLEVI (clascoterone) cream 1% monotherapy resulted in the following:
Inflammatory lesion count: mean percent change

STUDY DESIGN: In 2 identical, randomized, double-blind, vehicle controlled trials with a total of 1421 enrolled subjects 12 years of age and older with facial acne vulgaris, WINLEVI was statistically superior over vehicle for all 3 coprimary endpoints,3 including IGA success and absolute change from baseline in inflammatory and noninflammatory lesion counts.1 Mean percent change from baseline in total, inflammatory, and noninflammatory lesion counts, and absolute change from baseline in total lesion counts were secondary endpoints. Data shown are pooled efficacy results for patients ages 12 and older.
Focus on before-and-after results
See the difference for patients on twice-daily WINLEVI (clascoterone) cream 1% monotherapy at week 121
Most common adverse reactions occurring in 7% to 12% of patients are erythema/reddening, pruritus and scaling/dryness. Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.

Actual male patient from Winlevi clinical trial

Models shown are not actual patients.
WINLEVI: Twice daily for female AND male patients 12 years and older.1
Learn more